ArticleBlood advances2019

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.

Manali Kamdar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.